70 related articles for article (PubMed ID: 2869000)
1. Oxmetidine (SK&F 92994): pharmacokinetic study in patients with in patients with liver cirrhosis.
Miglio F; Baraldini M; Serra S; Facchini A; Stefanini GF; Meliconi R; Gasbarrini G; Labo' G
Int J Clin Pharmacol Res; 1985; 5(6):399-404. PubMed ID: 2869000
[TBL] [Abstract][Full Text] [Related]
2. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
[TBL] [Abstract][Full Text] [Related]
3. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
[TBL] [Abstract][Full Text] [Related]
4. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
5. Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.
Young CJ; Daneshmend TK; Roberts CJ
Gut; 1982 Oct; 23(10):819-23. PubMed ID: 6126422
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oxmetidine, a new histamine H2-receptor antagonist, after single oral and intravenous doses.
Jönsson KA; Bodemar G; Gotthard R; Norlander B; Walan A
Eur J Clin Pharmacol; 1983; 24(3):353-6. PubMed ID: 6134622
[TBL] [Abstract][Full Text] [Related]
8. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
Neal EA; Meffin PJ; Gregory PB; Blaschke TF
Gastroenterology; 1979 Jul; 77(1):96-102. PubMed ID: 447033
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic study on midazolam in compensated liver cirrhosis.
Rinetti M; Ascalone V; Colombi Zinelli L; Cisternino M
Int J Clin Pharmacol Res; 1985; 5(6):405-11. PubMed ID: 2936689
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Lacroix C; Tranvouez JL; Phan Hoang T; Duwoos H; Lafont O
Arzneimittelforschung; 1990 Jan; 40(1):76-9. PubMed ID: 2340003
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics in man of SK&F 93319--a new antagonist of histamine H1 and H2 receptors.
Johnson P; Griffiths R; Lee RM; McDowall RD; Doyle E; Taylor DC; Burland WL
Xenobiotica; 1984 Jul; 14(7):589-93. PubMed ID: 6150581
[TBL] [Abstract][Full Text] [Related]
13. Dipyrone metabolism in liver disease.
Zylber-Katz E; Caraco Y; Granit L; Levy M
Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
[TBL] [Abstract][Full Text] [Related]
14. Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver.
Hellstern A; Hellenbrecht D; Saller R; Gatzen M; Manus B; Achtert G; Brockmann P; Hausleiter HJ; Leuschner U
Arzneimittelforschung; 1987 Jun; 37(6):733-6. PubMed ID: 3663273
[TBL] [Abstract][Full Text] [Related]
15. Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer.
Gugler R; Rohner HG; Somogyi AA
Clin Pharmacol Ther; 1982 Apr; 31(4):501-8. PubMed ID: 6120776
[TBL] [Abstract][Full Text] [Related]
16. Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans.
Huupponen R; Karhuvaara S; Anttila M; Vuorilehto L; Scheinin H
Clin Pharmacol Ther; 1995 Nov; 58(5):506-11. PubMed ID: 7586944
[TBL] [Abstract][Full Text] [Related]
17. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
18. Furosemide disposition in cirrhotic patients.
Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
[TBL] [Abstract][Full Text] [Related]
19. Normal metabolism of morphine in cirrhosis.
Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man.
Necciari J; Mery D; Garriot P; Escourrou J; Cautreels W
Int J Clin Pharmacol Res; 1985; 5(6):457-65. PubMed ID: 2869002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
